Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief scientific officer starting Jan. 1.

Pfizer said on Wednesday it has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, as its chief of research and development. The appointment comes at a time when Pfizer is facing pressure from activist investor Starboard,

As for his soon-to-be former role, Boshoff will be succeeded by Dr. Roger Dansey, who will serve as the interim chief oncology officer. He will then hand off the role to Dr. Johanna Bendell, who will join the Pfizer team in 2025.

Pharmaceutical giant Pfizer (PFE) has named company veteran Chris Boshoff its chief of research and development (R&D) as it looks to produce new pr

Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the pharma through the COVID-19 pandemic. The move comes weeks after Pfizer faced pressure from activist investor Starboard Value.

Chris Boshoff will take on the role of chief scientific officer starting Jan 1 & oversee all functions of research & development across all therapeutic area

Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development, as the drugmaker faces pressure from investors to produce profitable new drugs.

Pfizer Inc. named oncology research head Chris Boshoff as the drug company’s chief scientific officer, replacing Mikael Dolsten, whose planned departure was announced earlier this year.